CN1045534C - Compound medicine for treating wart - Google Patents
Compound medicine for treating wart Download PDFInfo
- Publication number
- CN1045534C CN1045534C CN94100312A CN94100312A CN1045534C CN 1045534 C CN1045534 C CN 1045534C CN 94100312 A CN94100312 A CN 94100312A CN 94100312 A CN94100312 A CN 94100312A CN 1045534 C CN1045534 C CN 1045534C
- Authority
- CN
- China
- Prior art keywords
- wart
- treating
- present
- medicine
- grains
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a novel compound medicine for treating wart, which is an orally taken new medicine for treating flat wart. The present invention adopts reserpine, moroxydine and vitamin A which are prepared into grains or powder according to a certain unitage, and the grains or powder is mixed and prepared into coated tablets. The present invention has the characteristics of low cost, convenience for treatment, conspicuous curative effect, etc. The preparation dosage is reasonable, and compound medicines of various shapes for treating wart can be produced. Compared with the existing medicines for treating flat wart, the medicine has the advantages of low cost, little side effect, no scar after cure, easy acceptance of patients, etc. The present invention accords with the requirement for hygienic standards and is suitable for patients with flat wart to take.
Description
The present invention relates on the field of medicaments, particularly adapt to the oral drugs of treatment verruca plana.
Verruca plana is that human papillomavirus causes, is that the people is by on the immediate contagion.Unique host of this kind virus is the people, and the maturation and the skin of virus, and the epithelial cell keratinization degree of mucosa is relevant, and the course of disease and the immunity of organism of wart have important relationship.
In recent years, people always different angles research it to the various influences of human body, it is convenient that a kind of treatment is found out in examination, evident in efficacy, side effect is little, the patient that more easily makes of back preventing from scar accepts ideal Therapeutic Method.Just there is patient's recovery from illness of 54% nineteen twenty-seven with suggestive treatment treatment verruca plana patient in three months; 1934 with sulfur arsenic all to lean on bright injection effect also undesirable; 1985 with liquid nitrogen spraying method therapeutic effect certainly, but the operating technology complexity easily causes to infect to form cicatrix, is difficult for popularizing in an all-round way; Reached 95% with 5-FuOMSo exterior coating treatment total effective rate in 1986, but can make local skin have in various degree pigmentation, and increase the weight of with illumination, and relapse rate about 17%.
In order to address these problems, normally select the good hospital of equipment for use, be skilled in technique, adopt liquid nitrogen mist method, grasp the degree of depth, be difficult for forming cicatrix; But be difficult to implement this treatment for hospital of existing many subordinates.And adopt the 5-FuOMSo exterior coating treatment, easily form pigmentation and recurrence.
The purpose of this invention is to provide a kind of wart compositions of going, it can treat verruca plana effectively, and evident in efficacy, method is easy, and low toxicity easily makes advantages such as patient accepts.
The objective of the invention is to realize like this: adopt between reserpine (Reserpine) 0.125-0.25mg and between Moroxydine (Moroxyeline) 0.05-0.1g and vitamin A (VitaminA) 10000-20000 unit, make graininess or powder shape through operations such as pharmacy, at normal temperatures the mixed preparing sugar coated tablet.
It is a kind of pure alkaloid that the Rauvolfia serpentina root proposes that the present invention adopts reserpine, reserpine, and its pharmacological action (1) causes the sympathetic nerve mediator to consume brown and blood pressure lowering.(2) cause norepinephrine and 5-hydroxy tryptamine in the maincenter to be exhausted and produce stable effect like chlorpromazine, whether the treatment verruca plana does not still have report, stable with maincenter, and sympathetic mediator exhausts that to improve skin, mucosa, blood circulation relevant.Moroxydine has antivirus action, may suppress tRVA, and is synthetic relevant with mRNA.Vitamin A has the growth of promotion, keeps the normal function of epithelial tissue, and lacking then, growth stops pachylosis, keratinization etc.A lot of to vitamin A purposes report at present, as: anti-gastric-ulcer, the actinic cheilitis canceration, optimum mastadenoma etc., its mechanism are to regulate cell growth, metabolic process, and the vitamin A pair cell of high concentration and lysosome membrane have short molten effect, promote cellular content or lysosomal enzyme to overflow, cause aqtocytolysis destruction etc., can see cytotoxicity as, so can cause tumor regression.For going the wart compositions to observe three days 3.3%, one all 52%, two all 86.7%, three weeks of cure rate of cure rate of cure rate clinically is more than 95%, and total effective rate is 100%, thus from clinical observation along with prolong medicine time, the corresponding raising of cure rate.And be subject to the patient and accept good reliability.
Claims (1)
1, a kind of wart compositions of going, it is characterized in that: said composition is formulated by the component of following content:
Reserpine 0.125-1.25mg
Moroxydine 0.05-1.1g
Vitamin A 10000-20000 unit
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN94100312A CN1045534C (en) | 1994-01-16 | 1994-01-16 | Compound medicine for treating wart |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN94100312A CN1045534C (en) | 1994-01-16 | 1994-01-16 | Compound medicine for treating wart |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1096674A CN1096674A (en) | 1994-12-28 |
| CN1045534C true CN1045534C (en) | 1999-10-13 |
Family
ID=5029562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN94100312A Expired - Fee Related CN1045534C (en) | 1994-01-16 | 1994-01-16 | Compound medicine for treating wart |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1045534C (en) |
-
1994
- 1994-01-16 CN CN94100312A patent/CN1045534C/en not_active Expired - Fee Related
Non-Patent Citations (3)
| Title |
|---|
| 《临床皮肤科杂志》1992,21(4) 1992. 4. 1 张文禹等,《病毒灵霜治疗扁平疣37例疗效观察》 * |
| 《湖北医药导报》1991,10(3) 1991. 3. 1 田凤英等,《维生素A的临床应用》 * |
| 《湖北医药导报》1991,10(3) 1991. 3. 1 田凤英等,《维生素A的临床应用》;《临床皮肤科杂志》1992,21(4) 1992. 4. 1 张文禹等,《病毒灵霜治疗扁平疣37例疗效观察》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1096674A (en) | 1994-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2013000382A1 (en) | Fatty acid composition and plant extract and pharmaceutical preparation and application thereof | |
| CN110384725A (en) | A kind of preparation of Chinese traditional medicine composition and its activity extract for adjusting oral cavity flora | |
| CN105311081A (en) | Application of Shanhaidan chrysanthemum indicum injection in aerosol inhalation, spray bottle aerial fog and rectal administration and method | |
| EP2501366A1 (en) | Anti-viral composition and method | |
| CN1045534C (en) | Compound medicine for treating wart | |
| US20240189382A1 (en) | Formula for inhibiting aging regeneration repair | |
| CN1284585C (en) | Medicine for treating acute and chronic pharyogolaryngitis, recurring oral cavity sore and its preparation method | |
| CN1061720A (en) | Vitamin-mineral composition and clinical practice thereof | |
| CN107050060A (en) | Treat psoriasic externally applied drug and pharmaceutical composition | |
| CN104758348B (en) | A kind of Chinese medicine composition preparation is used for the purposes of tumor chemoradiotherapy related oral ulcer | |
| CN114209683A (en) | Application of azelaic acid in preparation of medicine for treating inflammatory bowel disease | |
| CN111803622A (en) | Liquid repairing film for oral ulcer | |
| CN1289144C (en) | Medicine for treating radioactive membrana mucosa damage, repeative aphtha and paradentitis | |
| CN115040501B (en) | Application of cis-13-octadecenoic acid or salt compound thereof in preparation of drugs for promoting healing of damaged skin and/or mucous membrane | |
| CN1861072A (en) | Use of malic polyphenols for preparing medicines to treat bronchitis or asthma | |
| CN107029058A (en) | A kind of Chinese medicine composition for treating chronic pharyngitis | |
| CN1246367A (en) | Medicine for treating tinea | |
| CN1861073A (en) | Use of malic polyphenols for preparing medicine to treat pharyngolaryngitis | |
| CN105687227A (en) | Oral mucosa ulcer paste and preparation method thereof | |
| CN1077117A (en) | The compound method of treatment psoriasis compound cantharides ointment | |
| CN1401361A (en) | Medicine for treating aphtha | |
| CN1122516C (en) | Medicine for treating stomatopathy and throat disease | |
| CN116139215A (en) | Traditional Chinese medicine composition of externally-applied anti-infection traditional Chinese medicine lotion, preparation method and application | |
| CN112121062A (en) | External-use medicine composition for treating bromhidrosis | |
| CN118021834A (en) | Anti-alcoholic liver-protecting composition containing pyrroloquinoline quinone disodium salt and application of composition in food and pharmaceutical preparations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |